FadD from Pseudomonas putida CA-3 Is a True Long-Chain Fatty Acyl Coenzyme A Synthetase That Activates Phenylalkanoic and Alkanolic Acids

Aisling R. Hume, Jasmina Nikodinovic-Runic, and Kevin E. O'Connor*

School of Biomolecular and Biomedical Science, Ardmore House, and Centre for Synthesis and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland

Received 31 July 2009/Accepted 1 October 2009

A fatty acyl coenzyme A synthetase (FadD) from Pseudomonas putida CA-3 is capable of activating a wide range of phenylalkanoic and alkanolic acids. It exhibits the highest rates of reaction and catalytic efficiency with long-chain aromatic and aliphatic substrates. FadD exhibits higher $k_{cat}$ and $K_m$ values for aromatic substrates than for the aliphatic equivalents (e.g., 15-phenylpentadecanoic acid versus pentadecanoic acid). FadD is inhibited noncompetitively by both acrylic acid and 2-bromoananoic acid. The deletion of the fadD gene from P. putida CA-3 resulted in no detectable growth or polyhydroxyalkanoate (PHA) accumulation with 10-phenyldecanoic acid, decanoic acid, and longer-chain substrates. The results suggest that FadD is solely responsible for the activation of long-chain phenylalkanoic and alkanolic acids. While the CA-3ΔfadD mutant could grow on medium-chain substrates, a decrease in growth yield and PHA accumulation was observed. The PHA accumulated by CA-3ΔfadD contained a greater proportion of short-chain monomers than did wild-type PHA. Growth of CA-3ΔfadD was unaffected, but PHA accumulation decreased modestly with shorter-chain substrates. The complemented mutant regained 70% to 90% of the growth and PHA-accumulating ability of the wild-type strain depending on the substrate. The expression of an extra copy of fadD in P. putida CA-3 resulted in increased levels of PHA accumulation (up to 1.6-fold) and an increase in the incorporation of longer-monomer units into the PHA polymer.

Fatty acyl coenzyme A (CoA) synthetases (FACS; fatty acid: CoA ligases; EC 6.2.1.3) are ATP-, CoA-, and Mg$^{2+}$-dependent enzymes that activate alkanolic acids to CoA esters for β oxidation (Fig. 1) (2, 17). FACS are widely distributed in both prokaryotic and eukaryotic organisms and exhibit a broad substrate specificity (34). FadD is a cytoplasmic membrane-associated FACS (7), with sizes ranging from 47 kDa to 62 kDa (2, 14). There is a lack of biochemical information on FadD with a preference for long-chain aromatic and aliphatic substrates. In the current study we purify and characterize for the first time a true long-chain FadD with activity toward both phenylalkanoic and alkanolic acids.

It is known that bacteria such as Pseudomonas putida can accumulate the biological polymer polyhydroxyalkanoate (PHA) from aromatic as well as aliphatic alkanolic acids (5, 6, 42, 45). The presence of aromatic monomers in the PHA polymer suggests that a FadD with activity toward aromatic substrates is present in these PHA-accumulating strains. Garcia et al. knocked out an acyl-CoA synthetase in P. putida U with a high homology to long-chain fadD products from Escherichia coli and Pseudomonas fragi (6). Garcia et al. also showed that the mutant was not capable of growth or PHA accumulation with aromatic and aliphatic substrates having between 5 and 10 carbons in their acyl chain, indicating that it is a general and not a long-chain acyl-CoA ligase (6). In a follow-up study, Olivera et al. showed that the fadD mutants reverted to wild-type characteristics within 3 days of incubation, indicating that fadD could be replaced by the activity of a second enzyme (25). Indeed, two fadD gene homologues have been identified in P. putida U, namely, fadD1 and fadD2, with fadD2 being expressed only when fadD1 is inactivated (25). A putative FadD in P. putida KT2440 is encoded by PP_4549 (24), but the protein has not been studied nor has the effect of fadD (PP_4549) expression/disruption been examined. In the current study the knockout and complementation of fadD from P. putida CA-3 demonstrated that its activity is critical for growth and PHA accumulation with long-chain aromatic and aliphatic alkanolic acids and that the activity is not replaced by a second enzyme. While reports have shown that PHA polymerase greatly affects PHA monomer composition (30, 40), no evidence of the specific effect of FACS on PHA accumulation so far exists.

We describe here the purification, kinetic characterization, gene deletion, and homologous expression of FadD from P. putida CA-3. This is a fundamental study of the activity and physiological role of FACS activity in aromatic and aliphatic alkanolic acid activation and PHA accumulation.

MATERIALS AND METHODS

Reagents. The phenylalkanoic acids 9-phenylnonanoic acid (C9Ph), 12-phenyldecanoic acid (C12Ph), 15-phenylpentadecanoic acid (C15Ph), and 16-phenylhexadecanoic acid (C16Ph) were all purchased from Apollo Scientific (Stockport, Cheshire, United Kingdom); all other phenylalkanoic acids were purchased from Alfa-Aesar (Heysham, Lancaster, United Kingdom). Pentadecanoic acid was purchased from Alfa-Aesar (Heysham, Lancaster, United Kingdom); all...
other aliphatic alkanolic acids (C₃ to C₁₆) were purchased from Sigma-Aldrich (Dublin, Ireland). Hydrochloric acid, sodium nitroprusside dihydrate, and ethylchloroformate were purchased from Sigma (Dublin, Ireland); methyl-3-hydroxyundecanoate and methyl-3-hydroxypentadecanoate were purchased from Larodan Fine Chemicals (Malmo, Sweden). Bio-X-ACT Long DNA polymerase was purchased from Bioline (London, England), the pGEM-T Easy vector system was purchased from Promega, and T4 DNA ligase was purchased from Stratagene (La Jolla, CA). Restriction enzymes NdeI, XhoI, NotI, BamHI, SmaI, and Clal were obtained from Invitrogen (Paisley, United Kingdom). Bug Buster, mouse monoclonal antibody immunoglobulin G (IgG) anti-His₆, and goat anti-mouse IgG were all purchased from Merck Biosciences (United Kingdom). Oligonucleotide primers were obtained from Sigma Genosys (Dublin, Ireland). The QIAprep spin plasmid miniprep kit and Qiagen II gel purification kit were purchased from Qiagen (Hilden, Germany). All other chemicals were purchased at the highest purity from Sigma-Aldrich (Dublin, Ireland). The digoxigenin DNA labeling and detection kit and positively charged nylon membrane were purchased from Roche Diagnostics (Mannheim, Germany).

Culture media and growth conditions. Strains, plasmids, and primers used in this study are listed in Table 1 and Table 2. Pseudomonas strains were grown in MSM liquid medium (36) and were stored frozen at −80°C in MSM medium containing 15% (vol/vol) glycerol. E. coli strains used for protein expression studies were grown in shake flasks (250 ml) containing 50 ml of Luria-Bertani (LB) complex medium (35) at 37°C with shaking at 200 rpm and supplemented with carbenicillin (50 μg ml⁻¹).

For the purpose of PHA accumulation experiments, MSM medium was used with the inorganic nitrogen source ammonium chloride supplied at a concentration of 0.25 g liter⁻¹ (65 mg N liter⁻¹). Except where otherwise stated, carbon substrates were included in the medium at a concentration of 2.28 g C liter⁻¹. Bacterial cultures were grown for 48 h at 30°C with shaking at 200 rpm. When appropriate, gentamicin (50 μg ml⁻¹) and kanamycin (75 μg ml⁻¹) were added to the medium for Pseudomonas deletion and complemented strains (Table 1). Carbon substrates were included in the medium at a concentration of 15 mmol liter⁻¹. Pseudomonas deletion and complemented strains were grown for the appropriate length of time (2 to 7 days) depending on the growth substrate used with shaking at 200 rpm.

DNA techniques and plasmid construction. All basic molecular biology techniques were performed as described by Sambrook et al. (35). Isolation of plasmid DNA from E. coli and Pseudomonas strains was carried out using a plasmid isolation procedure (Qiagen). Pseudomonas cells were made competent following a previously described procedure (3). Plasmids were transformed into electrocompetent E. coli and P. putida CA-3 cells using Gene Pulser II (Bio-Rad, Hercules, CA).

![FIG. 1. FadD activation of fatty acids to their CoA derivatives proceeds through ATP-dependent covalent binding of AMP to fatty acid with the release of inorganic pyrophosphate, followed by C-S bond formation to obtain fatty acyl-CoA ester and subsequent release of AMP. FadD requires the presence of Mg²⁺ ions to be active (2, 17).](image-url)
Hercules, CA), using a 2-mm-gap-width electrocapillary cuvette and applying a pulse (settings: 25 μF, 200 Ω, and 2.5 kV). For the generation of pJB861-fadD plasmid (Table 1), E. coli XLI-Blue MRF electrocompetent cells were used as cloning hosts and transformed according to the manufacturer’s instructions (Stratagene, Germany).

Genomic DNA was isolated from P. putida CA-3 by the method of Sambrook et al. (35). The primers FadD_NdeI (F) and FadD_XhoI (R) (Table 2) were designed based on the known fadD sequence of P. putida KT2440 and were used to amplify the fadD gene from P. putida CA-3. PCR was performed using a DNA Engine thermal cycler (Bio-Rad, Hercules, CA) using the following parameters: 95°C for 2 min; 30 cycles of 95°C for 30 s, 55°C for 40 s, and 72°C for 2 min; and a final extension at 72°C for 10 min. The 1.7-kb fragment generated by PCR was digested with NdeI and XhoI and ligated into pET22b to generate pET22b_FadD for expression in E. coli (Fig. 1). Similarly, primers FadD_JB_NotI (F) and FadD_JB_BamHI (R) (Table 2) were used to amplify fadD for cloning into the broad-range expression vector pBluescript II for expression in P. putida (Table 1). A control strain, CA-3+pJB, which contains a vector but no fadD gene inserted, was also included (Table 1). To verify plasmid constructs, DNA sequencing was conducted by GATC Biotech (Hamburg, Germany) using appropriate primers. Sequence data were aligned and compared to the GenBank database using the BLAST program (1).

fadD gene deletion. A 2.4-kb DNA fragment which contained the 1.7-kb sequence of fadD was amplified by PCR using genomic DNA of P. putida CA-3 as template and primers FadD_external_seq (F) and FadD_external_seq (R) (Table 2). PCR conditions consisted of one cycle of 95°C for 2 min followed by 30 cycles of 95°C for 30 s, 51°C for 40 s, 68°C for 1 min, and finally 68°C for 1 min. Purified PCR product was ligated into pGEM-T Easy vector (Promega), generating pGEM-fadD24 (Table 1).

Primers FadD_ext_Up inverse (R) and FadD_ext_Down inverse (F) (Table 2) were used to amplify a 4-kb DNA fragment using pGEM-fadD24 as template. PCR conditions consisted of one cycle of 95°C for 2 min followed by 30 cycles of 95°C for 30 s, 55°C for 40 s, 68°C for 4 min, and finally 68°C for 7 min. The PCR product obtained contained a SalI restriction site flanked by 55 bp from the beginning of the fadD gene, the rest of the pGEM vector, 38 bp from the end of the fadD gene, and another SalI restriction site. A 1,053-bp gentamicin resistance cassette was excised from the pPS856 plasmid by digestion with SalI and ligated with the 4-kb PCR product to generate plasmid pGEM-fadDl (Table 2). Verification of all generated vectors was carried out by restriction digestion and sequencing (GATC Biotech, Hamburg, Germany) using appropriate primers.

Plasmid pGEM-fadDl was introduced into electrocompetent P. putida CA-3 by electroporation to generate the deletion mutant CA-3-fadD (Table 1). Gentamicin-resistant colonies were selected and verified by plasmid preparation, PCR, and Southern blot analysis.

Complementation of CA-3-fadD deletion mutant. Complementation of CA-3-fadD was carried out using pJB861-fadD plasmid (Table 1). pJB861-fadD was introduced into CA-3-fadD by electroporation to generate CA-3-fadD+fadD. Selection of CA-3-fadD+fadD was carried out by screening for gentamicin and kanamycin resistance. An appropriate control strain (CA-3-fadD+pJB) which contains the expression vector without the fadD gene inserted, was also included in the study (Table 1).

Southern blot analysis. Genomic DNA from the wild type and the deletion mutant was digested with CiaI and resolved in an 0.8% agarose (Tris-acetate-EDTA) gel for 1.5 h at 60 V. DNA was transferred to a positively charged nylon membrane using the TurboBlotter Rapid Downward transfer system according to the manufacturer’s instructions (Schleicher & Schuell, Inc.), and DNA was then UV-cross-linked to the membrane. The gentamicin cassette was used as a hybridization probe and was digoxigenin labeled. The signal was detected using color substrate solution (nitroblue tetrazolium-3-bromo-4-chloro-3-indolylphosphate) according to the manufacturer’s instructions (Roche Applied Science, Fig. 2).

Overexpression of FadD in E. coli and subsequent purification. Cultures were prepared for use in experiments by inoculation of cells from frozen stock culture onto agar plates and then subcultured into broth and incubated at the appropriate temperatures. Seed cultures of E. coli BL21(DE3) cells expressing FadD from pET22b were grown overnight at 37°C in 50-ml cultures of LB supplemented with carbenicillin (50 μg ml−1). These were then inoculated into a 5-liter fermentor (ElectroLab Limited, Tewksbury, England) (1% inoculum) and grown in LB supplemented with carbenicillin (50 μg ml−1) at 37°C, with a 5-liter min−1 airflow and an agitation speed maintained at 400 rpm (11). Once the culture had reached an optical density of 0.6 (600 nm) Helios Gamma UV-visible spectrophotometer [Thermo Scientific, Ireland], the cells were induced with 1 mM IPTG (isopropyl-β-D-thiogalactopyranoside) and further incubated for 10 h at 24°C. The cells were then harvested by centrifugation at 10,000 × g for 15 min at 4°C in a Sorvall RC5C5 Plus centrifuge (Unitech, Ireland). The cells (2 g [wet weight]) were lysed using Bug Buster (7 ml) (Merck Biosciences, United Kingdom) supplemented with 2 ml binding buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 10 mM imidazole), 25 μl protease inhibitor (Sigma), 10 μl benzamidine nuclease (Sigma), and 1 to 2 mg of lysozyme (Sigma). After incubation with shaking at 30°C for 30 min, cell debris was removed by centrifugation at 20,000 × g for 30 min at 4°C. The supernatant was filtered through 0.45-μm sterile filters (Sartred). The filtered supernatant (6 ml) was loaded onto a Ni-MAC cartridge (1 ml; Merck Biosciences, United Kingdom) using the Aktaprime protein purification system (GE Healthcare, United Kingdom) equilibrated with binding buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 10 mM imidazole) at 0.5 ml min−1 with an imidazole step gradient from 0% to 100%. All the purification steps were carried out at 4°C. The eluted protein was put through Amicon ultracentrifugal filter devices (50 kDa; Millipore, Ireland), to remove any smaller background proteins and to concentrate the protein twofold. Charged amino acids t-arginine and l-glutamate (Sigma) at 50 mM were added to the eluted protein, to stabilize the protein, according to the method of Golovanov et al. (8).

Protein analysis. The protein concentration was determined as previously described (38). Concentrated protein (4 mg ml−1) was separated on a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel according to the protocol described by Laemmli (19). The proteins separated by SDS-polyacrylamide gel electrophoresis were electroblotted onto an Immobilon-P transfer polyvinylidene difluoride membrane (0.45-μm pore size; Millipore, Ireland). The membranes were incubated first with IgG anti-His 6 mouse monoclonal antibody as primary antibody and then with goat anti-mouse IgG as secondary antibody according to the manufacturer’s instructions. The membranes were finally treated with an Immobilon Western chemiluminescent kit (Millipore, Ireland) according to the manufacturer’s instructions, and the protein bands were visualized using the FluorChemFC2 imager (Alpha Innotech Medical Supply, Dublin, Ireland).

In order to confirm protein identity, protein bands were cut from the SDS-polyacrylamide gel and the proteins were digested in gel with trypsin according to the method of Shevchenko et al. (37). In-house proteomics pipeline software (Prolin) was used to process data. Briefly, spectra were searched using the XTandem algorithm (4) against the UniProt database restricted to P. putida entries (downloaded 7 January 2007). Only proteins (i) with an XTandem
probability score greater than 0.99, (ii) identified by a minimum of two spectra, and (iii) from *P. putida* were accepted. Spectral counts were automatically calculated for each peptide using Proline.

**Analysis of acyl-CoA synthetase activity.** Acyl-CoA synthetase activity was determined by measuring the rate of formation of the corresponding hydroxamate in the presence of ATP, CoA, substrate acid, and neutral hydroxylamine as previously described by Martinez-Blanco et al. (23). Phenylalkanoic or alkanonic acids (C_3_ to C_16_) were used as substrates. The reaction mixture contained 12.5 µl MgCl _2_ (0.2 M), 50 µl ATP (0.1 M), 30 µl CoA (20 mM), 30 µl substrate (ranging in concentration from 0.00075 to 0.25 mM), and 50 µl hydroxylamine solution (prepared as described below). Both ATP and CoA were dissolved in 50 mM Tris buffer, pH 8.0, was prepared by mixing 1 ml hydroxylamine hydrochloride (5 M), 250 µl of the solution to a strip of filter paper, which was then dipped in a sodium nitroprusside reagent (39), which reacts with free CoA to give a pink color. When the pink color could no longer be detected, all the free CoA was assumed to have reacted with the mixed anhydride to form the fatty acyl-CoA. This was confirmed by adding saturated NaOH solution (dissolved in methanol), which cleaves the thioester bond, causing free CoA to be released and the pink color to return.

**Inhibition activity assays.** The inhibitory effect of acrylic acid and 2-bromooctanoic acid was determined by measuring acyl-CoA synthetase activity and the rate of formation of the corresponding hydroxamate in the presence of ATP, CoA, 8-phenyloctanoic acid or octanoic acid, neutral hydroxylamine, and either acrylic acid or 2-bromooctanoic acid. The reaction mixture contained 12.5 µl MgCl _2_ (0.2 M), 50 µl ATP (0.1 M), 30 µl CoA (20 mM), 30 µl substrate—was omitted in the assay, and the assay mixture was incubated as described for test assays. Additionally, a control reaction mixture containing all components and heat-treated enzyme (75°C for 10 min) was also included. Reactions were stopped by adding 450 µl of the ferric chloride reagent (see below), and reaction mixtures were kept on ice for 30 min. The reaction mixtures were then centrifuged for 10 min at 14,000 × g in an Eppendorf 5415D microcentrifuge. The red-purple color formed was measured at 540 nm with a Helios Gamma UV-visible spectrophotometer (Thermo Scientific, Ireland). The molar extinction coefficients of the corresponding fatty acyl-hydroxamate (phenylalkanoic or alkanonic acids, C_3_ to C_16_) were determined experimentally as described below (Table 3). One unit of enzyme activity is defined as the catalytic activity leading to the formation of 1 nmol of fatty acyl-hydroxamate in 1 min. Specific activity is given as unit/mg of protein. Neutral hydroxylamine solution, pH 8.0, was prepared by mixing 1 ml hydroxylamine hydrochloride (5 M), 250 µl Millipore water, and 1.25 ml of KOH (4 M). Ferric chloride reagent was prepared by mixing a 1:1:1 ratio of ferric chloride (0.37 M), trichloroacetic acid (0.02 M), and hydrochloric acid (0.66 M) (22).

**Chemical synthesis of fatty acyl-CoA thioesters.** Fatty acyl-CoAs were synthesized as described previously by Stadtman (39) The phenylalkanoic or alkanonic acids were reacted with pyridine and ethylchloroformate to form the corresponding mixed anhydride. The anhydride was then reacted with free CoA to form the corresponding fatty acyl-CoA. The mixed anhydride was added to a 20 mM CoA solution, pH 7.5 (adjusted with 1 M KHCO _3_), until free CoA could no longer be detected by adding 5 µl of the solution to a strip of filter paper, which was then dipped in a sodium nitroprusside reagent (39), which reacts with free CoA to give a pink color. When the pink color could no longer be detected, all the free CoA was assumed to have reacted with the mixed anhydride to form the fatty acyl-CoA. This was confirmed by adding saturated NaOH solution (dissolved in methanol), which cleaves the thioester bond, causing free CoA to be released and the pink color to return.

**TABLE 3. Molar extinction coefficient values for aliphatic and aromatic compounds**

<table>
<thead>
<tr>
<th>Aliphatic compound (acid)</th>
<th>ε value (mM⁻¹ cm⁻¹)</th>
<th>Aromatic compound (acid)</th>
<th>ε value (mM⁻¹ cm⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propionic</td>
<td>1.84</td>
<td>3-Ph propionic</td>
<td>0.81</td>
</tr>
<tr>
<td>Butyric</td>
<td>1.55</td>
<td>4-Ph butyric</td>
<td>0.78</td>
</tr>
<tr>
<td>Valeric</td>
<td>0.92</td>
<td>5-Ph valeric</td>
<td>0.72</td>
</tr>
<tr>
<td>Hexanoic</td>
<td>2.65</td>
<td>6-Ph hexanoic</td>
<td>0.58</td>
</tr>
<tr>
<td>Heptanoic</td>
<td>2.70</td>
<td>7-Ph heptanoic</td>
<td>0.49</td>
</tr>
<tr>
<td>Octanoic</td>
<td>1.56</td>
<td>8-Ph octanoic</td>
<td>0.46</td>
</tr>
<tr>
<td>Nonanoic</td>
<td>1.19</td>
<td>9-Ph nonanoic</td>
<td>0.45</td>
</tr>
<tr>
<td>Decanoic</td>
<td>1.10</td>
<td>10-Ph decanoic</td>
<td>0.42</td>
</tr>
<tr>
<td>Undecanoic</td>
<td>0.82</td>
<td>11-Ph undecanoic</td>
<td>0.37</td>
</tr>
<tr>
<td>Dodecanoic</td>
<td>0.85</td>
<td>12-Ph dodecanoic</td>
<td>0.36</td>
</tr>
<tr>
<td>Myristic</td>
<td>0.79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentadecanoic</td>
<td>0.72</td>
<td>15-Ph pentanoic</td>
<td>0.36</td>
</tr>
<tr>
<td>Palmitic</td>
<td>0.42</td>
<td>16-Ph hexanoic</td>
<td>0.34</td>
</tr>
</tbody>
</table>

*Ph, phenyl. All data are the averages of at least three determinations.*
inhibitor with substrate concentrations varying between 0.00075 and 0.25 mM. Both ATP and CoA were dissolved in 50 mM Tris buffer, pH 8.2. After 5 min of temperature equilibration in a 30°C water bath, 100 μl of purified enzyme at a concentration of 4 mg ml⁻¹ was added to the assay vial and incubated for 5 min. Reactions were stopped by adding 450 μl of the ferric chloride reagent (as previously described), and reaction mixtures were kept on ice for 30 min (23). The reaction mixtures were then centrifuged for 10 min at 14,000 × g in an Eppendorf 5415D microcentrifuge. The red-purple color formed was measured at 540 nm with a Helios Gamma UV-visible spectrophotometer (Thermo Scientific, Ireland). Control experiments were carried out in the absence of acrylic acid and 2-bromooctanoic acid.

**RESULTS**

Cloning and sequencing of the *fadD* gene from *P. putida* CA-3. The DNA sequence (1,698 bp) of the *P. putida* CA-3 *fadD* gene was submitted to GenBank (accession number EU605979). DNA sequence analysis showed 99% homology between the *fadD* genes of *P. putida* CA-3 and *P. putida* KT2440 (see Fig. S1 in the supplemental material).

**Purification of FadD and characterization of its biochemical properties.** The *fadD* gene from *P. putida* CA-3 was expressed in pET22b under the control of the T7 promoter in *E. coli* BL21(DE3) (Table 1). The recombinant FadD protein had a C-terminal tag consisting of six consecutive histidines. The His-tagged FadD was purified to homogeneity by affinity chromatography using a nickel-chelating column (Merck Biosciences, United Kingdom). A protein product of approximately 62 kDa was observed on a denaturing SDS-polyacrylamide gel (see Fig. S2 in the supplemental material). This is in agreement with the molecular mass of FadD deduced from its amino acid sequence (62 kDa). The molecular mass was also verified by Western blot analysis using an IgG anti-His₆ antibody (Merck Biosciences, United Kingdom) (see Fig. S2 in the supplemental material), and protein identification was confirmed by mass spectrometry analysis.

In order to quantify FadD activity, the molar extinction coefficient of the CoA esters of each phenylalkanoic and alkanoic acid had to be determined experimentally (Table 3). Following the determination of the molar extinction coefficient values, the substrate range of purified FadD (4 mg ml⁻¹) was investigated using both phenylalkanoic and alkanoic acids. FadD from *P. putida* CA-3 showed activity toward long-, medium-, and short-chain phenylalkanoic and alkanoic substrates (Fig. 3). The protein exhibited a gradual increase in activity with increasing side chain length of the phenylalkanoic substrate (C₃Ph to C₁₁Ph) (Fig. 3). A more dramatic 2.4-fold increase in activity was observed when 12-phenyldodecanoic acid was used as a substrate in comparison to 11-phenylundecanoic acid. FadD exhibited a 1.25-fold-lower rate of activity with 15-phenylpentadecanoic acid than with 12-phenyldodecanoic acid (Fig. 3). In general FadD also exhibited an increase in activity with increasing chain length of the aliphatic substrates. The highest activity was observed with palmitic acid (C₁₆₆) as a substrate (Fig. 3).

Representative substrates were chosen for kinetic characterization of FadD from *P. putida* CA-3 (Table 4). Higher *k*_{cat}
higher concentration of acrylic acid was needed to completely inhibit FadD activity with octanoic acid (Fig. 4A).

2-Bromooccanoic acid exhibited strong inhibition of enzyme activity toward octanoic acid at 1.25 μM but was less effective at inhibiting FadD activity with 8-phenyloctanoic acid at inhibitor concentrations up to 0.5 mM (Fig. 4B). A dramatic increase in inhibition was observed when the concentration of 2-bromooccanoic acid was increased to 1 mM. Indeed, the complete inhibition of FadD with 8-phenyloctanoic acid and octanoic acid was observed at 1 mM 2-bromooccanoic acid (Fig. 4B).

Analysis of Lineweaver-Burk plots (1/V versus 1/S) revealed that both acrylic acid and 2-bromooccanoic acid are noncompetitive inhibitors of FadD, i.e., a reduction in $V_{\text{max}}$ values, without a change in the binding affinity ($K_m$) of the enzyme for the substrate, was observed (see Fig. S3A and B in the supplementary material).

Thus far, this study has established that a single enzyme, FadD, is capable of activating both aromatic and aliphatic alkanolic acids with markedly higher activity toward long-chain substrates than toward medium- and short-chain substrates. Whether FadD in *P. putida* CA-3 is the only FACS capable of activating long-chain aromatic and aliphatic alkanolic acids was investigated through the creation of a gene-specific deletion mutant (CA-3fadD). The creation of the mutant allowed us to define exactly the role of FadD in phenylalkanoic and alkanolic acid metabolism as well as its effect on accumulation of the biological polymer PHA.

**The effect of fadD gene deletion in *P. putida* CA-3 on growth and PHA accumulation.** The gene encoding the FACS FadD

---

**TABLE 4. Kinetic rates for FACS FadD from *P. putida* CA-3 for a range of phenylalkanoic and alkanolic acids**

<table>
<thead>
<tr>
<th>Acid substrate</th>
<th>$k_{\text{cat}}$ (min$^{-1}$) mean ± SD</th>
<th>$K_m$ (mM) mean ± SD</th>
<th>$k_{\text{cat}}/K_m$ (min$^{-1}$/mM$^{-1}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-Ph valeric</td>
<td>24 ± 1</td>
<td>84 ± 2</td>
<td>286</td>
</tr>
<tr>
<td>8-Ph octanoic</td>
<td>42 ± 1</td>
<td>79 ± 1</td>
<td>532</td>
</tr>
<tr>
<td>12-Ph dodecanoic</td>
<td>112 ± 3</td>
<td>55 ± 1</td>
<td>2,036</td>
</tr>
<tr>
<td>15-Ph pentadecanoic</td>
<td>108 ± 2</td>
<td>66 ± 2</td>
<td>1,636</td>
</tr>
<tr>
<td>Valeric</td>
<td>3 ± 1</td>
<td>32 ± 1</td>
<td>94</td>
</tr>
<tr>
<td>Octanoic</td>
<td>25 ± 1</td>
<td>26 ± 1</td>
<td>962</td>
</tr>
<tr>
<td>Nonanoic</td>
<td>15 ± 1</td>
<td>35 ± 2</td>
<td>429</td>
</tr>
<tr>
<td>Myristic</td>
<td>52 ± 2</td>
<td>46 ± 1</td>
<td>1,130</td>
</tr>
<tr>
<td>Pentadecanoic</td>
<td>61 ± 1</td>
<td>32 ± 1</td>
<td>1,906</td>
</tr>
<tr>
<td>Palmitic</td>
<td>124 ± 3</td>
<td>62 ± 2</td>
<td>2,000</td>
</tr>
</tbody>
</table>

*Ph, phenyl. All data are the averages of at least three determinations. All data have been rounded to the nearest whole number.

---

### Figure 4

**FIG. 4.** The inhibitory effects of acrylic acid (A) and 2-bromooccanoic acid (B) on FACS activity from *P. putida* CA-3 using either 8-phenyloctanoic acid (open bars) or octanoic acid (solid bars) as substrate (0.25 mM). All data are the averages of at least three independent determinations.
was specifically deleted from the genome of *P. putida* CA-3, creating the mutant CA-3ΔfadD. Specific deletion was confirmed by Southern blot analysis (Fig. 2A). The expected ClaI fragment containing the gentamicin cassette from CA-3ΔfadD was 3 kb in size (Fig. 2B). Complementation of the CA-3ΔfadD deletion mutant was performed by expressing fadD on pJB861 to create the strain CA-3ΔfadD+fadD (Table 1). The deletion mutant, complemented mutant, and the wild-type strain *P. putida* CA-3 were supplied with a range of phenylalkanoic acids (C₉Ph to C₁₂Ph) and alkanoic acids (C₃ to C₁₆) and tested for growth and PHA accumulation.

### Table 5. Biomasses and percentages PHA accumulated for *P. putida* CA-3, CA-3ΔfadD, CA-3ΔfadD+fadD, and CA-3+fadD grown on a range of phenylalkanoic acids

<table>
<thead>
<tr>
<th>Aromatic compound</th>
<th>CA-3</th>
<th>CA-3ΔfadD</th>
<th>CA-3ΔfadD+fadD</th>
<th>CA-3+fadD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Biomass, g liter⁻¹</td>
<td>% PHA</td>
<td>Biomass, g liter⁻¹</td>
<td>% PHA</td>
</tr>
<tr>
<td>12-Ph dodecanoic</td>
<td>1.48 ± 0.04</td>
<td>52 ± 2</td>
<td>0.00</td>
<td>0.0</td>
</tr>
<tr>
<td>10-Ph decanoic</td>
<td>1.50 ± 0.02</td>
<td>42 ± 1</td>
<td>0.00</td>
<td>0.0</td>
</tr>
<tr>
<td>9-Ph nonanoic</td>
<td>1.49 ± 0.05</td>
<td>39 ± 1</td>
<td>0.85 ± 0.02</td>
<td>12 ± 0.5</td>
</tr>
<tr>
<td>8-Ph octanoic</td>
<td>1.32 ± 0.03</td>
<td>35 ± 2</td>
<td>1.03 ± 0.04</td>
<td>11 ± 0.2</td>
</tr>
<tr>
<td>7-Ph heptanoic</td>
<td>0.93 ± 0.04</td>
<td>30 ± 1</td>
<td>0.76 ± 0.02</td>
<td>12 ± 0.4</td>
</tr>
<tr>
<td>6-Ph hexanoic</td>
<td>0.1 ± 0.03</td>
<td>26 ± 1</td>
<td>0.57 ± 0.03</td>
<td>18 ± 0.5</td>
</tr>
<tr>
<td>5-Ph valeric</td>
<td>0.80 ± 0.02</td>
<td>18 ± 2</td>
<td>0.80 ± 0.02</td>
<td>14 ± 0.3</td>
</tr>
</tbody>
</table>

* a Time allowed for growth, 48 h.
* b Time allowed for growth, 7 days.
* c Time allowed for growth, 168 h.
* d Ph, phenyl; NG, no growth. All data are means ± standard deviations and are the averages of at least three determinations. All PHA data have been rounded to the nearest whole number.

was specifically deleted from the genome of *P. putida* CA-3, creating the mutant CA-3ΔfadD. Specific deletion was confirmed by Southern blot analysis (Fig. 2A). The expected ClaI fragment containing the gentamicin cassette from CA-3ΔfadD was 3 kb in size (Fig. 2B). Complementation of the CA-3ΔfadD deletion mutant was performed by expressing fadD on pJB861 to create the strain CA-3ΔfadD+fadD (Table 1). The deletion mutant, complemented mutant, and the wild-type strain *P. putida* CA-3 were supplied with a range of phenylalkanoic acids (C₉Ph to C₁₂Ph) and alkanoic acids (C₃ to C₁₆) and tested for growth and PHA accumulation.

### Table 6. Biomasses and percentages PHA accumulated for *P. putida* CA-3, CA-3ΔfadD, CA-3ΔfadD+fadD, and CA-3+fadD grown on a range of aliphatic acids

<table>
<thead>
<tr>
<th>Aliphatic compound</th>
<th>CA-3</th>
<th>CA-3ΔfadD</th>
<th>CA-3ΔfadD+fadD</th>
<th>CA-3+fadD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Biomass, g liter⁻¹</td>
<td>% PHA</td>
<td>Biomass, g liter⁻¹</td>
<td>% PHA</td>
</tr>
<tr>
<td>Palmitic</td>
<td>2.27 ± 0.1</td>
<td>26 ± 1</td>
<td>0.00</td>
<td>0.0</td>
</tr>
<tr>
<td>Myristic</td>
<td>1.73 ± 0.1</td>
<td>37 ± 1</td>
<td>0.00</td>
<td>0.0</td>
</tr>
<tr>
<td>Dodecanoic</td>
<td>1.69 ± 0.05</td>
<td>37 ± 1</td>
<td>0.00</td>
<td>0.0</td>
</tr>
<tr>
<td>Decanoic</td>
<td>1.8 ± 0.04</td>
<td>32 ± 2</td>
<td>0.00</td>
<td>0.0</td>
</tr>
<tr>
<td>Nonanoic</td>
<td>1.79 ± 0.03</td>
<td>31 ± 2</td>
<td>0.49 ± 0.02</td>
<td>8 ± 0.1</td>
</tr>
<tr>
<td>Octanoic</td>
<td>1.59 ± 0.04</td>
<td>32 ± 1</td>
<td>1.03 ± 0.04</td>
<td>11 ± 0.1</td>
</tr>
<tr>
<td>Heptanoic</td>
<td>1.01 ± 0.04</td>
<td>20 ± 1</td>
<td>0.66 ± 0.02</td>
<td>10.5 ± 0.2</td>
</tr>
<tr>
<td>Hexanoic</td>
<td>0.91 ± 0.03</td>
<td>22 ± 1</td>
<td>0.56 ± 0.01</td>
<td>12 ± 0.3</td>
</tr>
<tr>
<td>Valeric</td>
<td>0.84 ± 0.02</td>
<td>19 ± 0.4</td>
<td>0.68 ± 0.01</td>
<td>13.5 ± 0.04</td>
</tr>
<tr>
<td>Butyric</td>
<td>0.77 ± 0.02</td>
<td>7.4 ± 1</td>
<td>0.73 ± 0.02</td>
<td>4.8 ± 0.1</td>
</tr>
<tr>
<td>Propionic</td>
<td>0.73 ± 0.02</td>
<td>6 ± 0.1</td>
<td>0.71 ± 0.02</td>
<td>3.5 ± 0.07</td>
</tr>
</tbody>
</table>

* a Time allowed for growth, 48 h.
* b Time allowed for growth, 7 days.
* c Time allowed for growth, 168 h.
* d NG, no growth; ND, not determined. All data are means ± standard deviations and are the averages of at least three determinations. All PHA data have been rounded to the nearest whole number.
to grow on long-chain phenylalkanoic acids (C_{10}Ph and C_{12}Ph) and alkanoic acids (C_{10} to C_{16}). The complemented mutant (CA-3ΔfadD/fadD) regained 70% to 90% of the growth and PHA-accumulating capacity of the wild-type strain depending on the substrate (Tables 5 and 6). The control mutant strain carrying the pJB861 plasmid without the fadD gene did not grow on long-chain aromatic (C_{10}Ph and C_{12}Ph) and aliphatic (C_{10} to C_{16}) alkanoic acids. The control strain grew and accumulated PHA in a manner similar to that of the knockout mutant with medium-chain phenylalkanoic and alkanoic acid substrates (C_{6} to C_{9}Ph and C_{6} to C_{9} to C_{12}Ph; data not shown).

When the deletion mutant CA-3ΔfadD was grown on medium-chain phenylalkanoic and alkanoic acids (C_{1}Ph to C_{6}Ph and C_{6} to C_{12}Ph), there was a longer lag period before growth entered the log phase. The mutant required 7 days to achieve approximately 60% of the biomass of the wild type (2 days). The biomass yield of the deletion mutant (total cell material minus PHA) decreased by 1.2- to 1.8-fold for phenylalkanoic acids and 1.5- to 3.8-fold for alkanoic acids in comparison to the wild type (Tables 5 and 6). The complemented mutant achieved a 1.4- and 1.6-fold-higher growth yield than did the deletion mutant when supplied with 9-phenylnonanoic acid and nonanoic acid, respectively (Tables 5 and 6). The deletion of fadD also resulted in a decreased growth yield of P. putida CA-3 when 7-phenylheptanoic acid, 8-phenyl octanoic acid, and aliphatic substrates hexanoic acid to octanoic acid were supplied as growth substrates. However, the complemented mutant did not achieve a higher biomass than did the mutant strain when supplied with any aromatic substrate with an acyl chain of eight carbons or fewer (Table 5) or an aliphatic substrate with seven carbons or fewer (Table 6).

CA-3ΔfadD supplied with medium-chain-length substrates (C_{2}Ph to C_{5}Ph and C_{7} to C_{9}) accumulated 3.9- to 2.5-fold less PHA than did the wild-type strain (Table 5). When medium-chain-length phenylalkanoic acids were supplied to CA-3ΔfadD, an increase in the proportion of shorter-chain aromatic monomers was detected. For example, a 5.2-fold increase and a 1.2-fold increase in the percentage of (R)-3-hydroxy-5-phenylvaleric acid and (R)-3-hydroxy-7-phenylheptanoic acid monomer units were observed when 9-phenyl nonanoic acid was used as a substrate in comparison to the levels produced by the wild type (Fig. 5C).

The complemented mutant (CA-3ΔfadD/fadD) accumulated 1.6- to 2-fold-more PHA than did the deletion mutant when supplied with C_{2}Ph to C_{5}Ph. The PHA accumulated by the complemented mutant contained proportionally more medium-chain monomers than did that accumulated by the deletion mutant but fewer than that of the wild-type strain (Fig. 5C and D). CA-3ΔfadD/fadD exhibited 2.3-fold and 2.4-fold increases in PHA accumulation levels with C_{8} and C_{9} as substrates compared to the mutant strain (Table 6).

**Short-chain phenylalkanoic acid and alkanoic acid substrates.** The growth of CA-3ΔfadD was unaffected when short-chain aromatic (C_{2}Ph and C_{3}Ph) and aliphatic (C_{5} to C_{9}) acids were supplied as substrates. PHA accumulation by the deletion mutant CA-3ΔfadD was affected 1.2- to 1.4-fold with these short-chain substrates (Tables 5 and 6; Fig. 5).

While the purified enzyme FadD has a broad substrate range, activating long-, medium-, and short-chain aromatic and aliphatic substrates (Fig. 3), its physiological role is critical only for the activation of long-chain aromatic and aliphatic substrates.

**The effect of expression of fadD in P. putida CA-3 on PHA accumulation and monomer composition.** As the deletion of fadD resulted in a decrease in the level of PHA and the appearance of shorter-chain monomers, the expression of an extra copy of fadD in the wild-type strain was undertaken to determine if an increase in PHA accumulation levels and the proportion of long-chain monomers could be achieved.

A recombinant strain of P. putida CA-3 expressing an extra copy of fadD was constructed (Table 1). The wild type and the recombinant strain (CA-3+fadD) were grown on a range of phenylalkanoic and alkanoic acids to determine growth yields, PHA accumulation, and monomer composition levels.

**Phenylalkanoic acids.** In general the expression of an extra copy of FadD (CA-3+fadD) results in a modest increase (1.1- to 1.3-fold) in PHA accumulation when phenylalkanoic acids are supplied (Table 5). This effect was not observed in the control strain P. putida CA-3 carrying pJB861 without a fadD gene. PHA accumulated by the wild type and the recombinant strain (CA-3+fadD) from phenylalkanoic acids was composed predominantly of monomer units equal in length to the carbon substrate supplied, e.g., (R)-3-hydroxy-10-phenyldecanoic acid was the predominant monomer in strains supplied with 10-phenyldecanoic acid. However, PHA accumulated by the recombinant strain (CA-3+fadD) also contained monomers two carbons longer than the predominant monomer. This was not observed in the wild-type or control strain expressing pJB861 without the fadD gene (Fig. 5A to D).

**Alkanoic acids.** The expression of an extra copy of FadD also resulted in a modest increase (up to 1.3-fold) in PHA accumulation when alkanoic acids were supplied (Table 6). The recombinant (CA-3+fadD) and wild-type strains accumulated PHA with the predominant monomer equal in chain length to the carbon substrate supplied in the range of C_{8} to C_{10} (Fig. 5E and F). This was not observed in the control strain expressing the pJB861 vector without the fadD gene. The overexpression of FadD resulted in an increase in (R)-3-hydroxydecanoic acid monomer when supplied with C_{8} to C_{10} (Fig. 5F to H). An increase in the proportion of (R)-3-hydroxyhexadecanoic acid was observed in the recombinant strain (CA-3+fadD) when dodecanoic acid was used as a carbon source (Fig. 5E).

The predominant monomer in PHA accumulation from myristic and palmitic acid was (R)-3-hydroxyoctanoic acid (data not shown). The recombinant strain (CA-3+fadD) accumulated higher proportions of (R)-3-hydroxydecanoic acid, (R)-3-hydroxytetradecanoic acid, and (R)-3-hydroxyhexadecanoic acid than did wild-type strains when supplied with myristic acid and palmitic acid (data not shown).

**DISCUSSION**

FadD activity toward aromatic and aliphatic alkanoic acids. We have shown for the first time that a single enzyme, FadD, is capable of activating both aromatic and aliphatic alkanoic acids. While FadD exhibited activity toward a range of phenylalkanoic acids, it showed a higher activity toward the long-chain substrates, i.e., C_{12}Ph and C_{13}Ph (Fig. 3). Interestingly, FadD exhibited higher activity for C_{12}Ph and C_{13}Ph than for...
the aliphatic equivalents (Fig. 3). Thus, the aromatic substituent appears to positively affect the rate of enzyme activity, while the turnover number \( k_{\text{cat}} \) of FadD increases with increasing chain length of the phenylalkanoic acid substrate.

However, the \( K_m \) value of FadD was in general higher for aromatic substrates than for aliphatic substrates, suggesting that the aromatic ring decreases the affinity of FadD for that substrate (Table 4). For aromatic substrates, it is possible only

FIG. 5. PHA accumulation and monomer distribution for *P. putida* CA-3, deletion mutant (CA-3ΔfadD), complemented deletion mutant (CA-3ΔfadD/H11001fadD), and *P. putida* CA-3 carrying an extra copy of the *fadD* gene (CA-3+fadD) grown on a range of phenylalkanoic and alkanoic acids: 12-phenyldodecanoic acid (A), 10-phenyldecanoic acid (B), 9-phenylnonanoic acid (C), 8-phenyloctanoic acid (D), dodecanoic acid (E), decanoic acid (F), nonanoic acid (G), and octanoic acid (H). C₄, \((R)-3\)-hydroxybutyric acid, etc.; C₃Ph, \((R)-3\)-hydroxy-3-phenylpropionic acid, etc.; *, cells grown on glucose and supplemented with either 12-phenyldodecanoic acid or dodecanoic acid for PHA accumulation (see Fig. S4 and Table S1 in the supplemental material). All data are the averages of at least three independent determinations.
to compare the enzyme activity of FadD from \emph{P. putida} CA-3 to one other source, namely, a short-chain acyl-CoA synthetase from \emph{Pseudomonas chlororaphis} B23 (9). \emph{P. putida} CA-3 FadD exhibited a 13-fold-higher rate of reaction with 3-phenylpropionic acid than with propionic acid (Fig. 3). In contrast, the short-chain acyl-CoA synthetase from \emph{P. chlororaphis} B23 showed a 2,952-fold-lower activity with 3-phenylpropionic acid (4.2 nmol min\(^{-1}\) mg protein\(^{-1}\)) than with its aliphatic equivalent propionic acid (9). Purified acyl-CoA synthetase from \emph{E. coli} exhibited maximum activity toward dodecanoic acid (2,632 nmol min\(^{-1}\) mg protein\(^{-1}\)) (14). However, FadD from \emph{P. putida} CA-3 exhibited the highest activity values with \(C_{12}\)Ph, \(C_{15}\), and \(C_{16}\) acids, respectively (Table 4). FadD from \emph{P. putida} CA-3 had \(K_m\) values similar to that reported in the literature for acyl-CoA synthetases from \emph{E. coli} acting on aliphatic substrates from \(C_6\) to \(C_9\) but higher \(K_m\) values for aliphatic substrates ranging from \(C_{14}\) to \(C_{16}\) (14).

The effect of inhibitors on the activity of FadD. Acrylic acid was previously shown to inhibit the first and last enzymes of \(\beta\) oxidation, namely, acyl-CoA synthetase (FadD) and 3-ketoacyl-CoA synthetase (FadA), in whole-cell assays (12, 28). 2-Bromoacetoanoic acid has been reported to inhibit the fatty acid synthesis enzyme (\(R\))-3-hydroxyacyl-ACP-CoA transferase (PhaG) and the \(\beta\)-oxidation enzyme 3-ketothiolase I (21, 29, 42). As \(\beta\)-oxidation and fatty acid synthesis pathways are providing intermediates for the PHA synthesis, both of these inhibitors have been extensively used in attempts to modulate PHA accumulation levels (26, 33). In general, when used in whole-cell assays at concentrations of 4 to 5 mM, acrylic acid causes either complete inhibition or considerably decreased levels of PHA accumulation from alkanoic and phenylalkanoic acid substrates (12, 21, 42). 2-Bromoacetoanoic acid caused a 20% decrease in cell dry weight and PHA accumulation when \emph{P. fluorescens} BM07 was grown on alkanoic and phenylalkanoic acid substrates (21).

We have shown for the first time that acrylic acid is an inhibitor of the purified enzyme FadD from \emph{P. putida} CA-3. Thijsse put forward the presumption that the possible mechanism of inhibition of acrylic acid with acyl-CoA synthetase and 3-ketoacyl-CoA synthetase is via an interaction of the double bond of acrylic acid with CoASH (41). There have been no studies of the inhibitory effect of 2-bromoacetoanoic acid on purified FACS. Raaka and Lowenstein proposed that 2-bromoacetoanoic acid is converted to 2-bromoacetoyl-CoA and 2-bromo-3-ketoacetoyl-CoA in rat liver mitochondria and that this 2-bromo-3-ketoacetoyl-CoA is the specific inhibitor of the enzyme 3-ketothiolase I (21, 29). It was suggested by Lee et al. that acetyl-ACP-CoA transferase (PhaG) is also inhibited by 2-bromo-3-ketoacetoyl-CoA (21). FadD from \emph{P. putida} CA-3 may also be inhibited by 2-bromoacetoyl-CoA formed by the action of FadD on 2-bromoacetoanoic acid. In support of this possibility, a low level of activity for FadD toward 2-bromoacetoanoic acid was observed when 2-bromoacetoanoic acid was incubated with FadD from \emph{P. putida} CA-3 (data not shown). Kasuya et al. reported that purified medium-chain acyl-CoA synthetase from bovine liver mitochondria was inhibited by 2-hydroxyoctanoic acid (\(K_i\), 500 \(\mu\)M) when hexanoic acid was used as a substrate (15). In comparison to 2-hydroxyoctanoic acid and other inhibitors, both acrylic acid and 2-bromoacetoanoic acid are more potent (15, 16). Kasuya et al. demonstrated that 2-hydroxyoctanoic acid is a competitive inhibitor of mitochondrial medium-chain acyl-CoA synthetase (15). However, acrylic acid and 2-bromoacetoanoic acid are noncompetitive inhibitors of FadD from \emph{P. putida} CA-3 with both 8-phenylacetoanoic acid and octanoic acid as substrates.

The effect of \(fadD\) gene deletion on growth and PHA accumulation. (i) Growth. The lack of growth on long-chain aromatic (\(C_{10}\)Ph and \(C_{12}\)Ph) and aliphatic (\(C_{10}\) to \(C_8\)) alkanoic acids indicates that FadD is essential for growth on these substrates. Therefore we have established that FadD from \emph{P. putida} CA-3 is truly a long-chain acyl-CoA synthetase. Despite extended incubation (7 days), the deletion mutant did not revert to growth or PHA accumulation levels of the wild-type strain. This differs from the work of Olivera et al., who observed reversion of the \(fadD\) transposon insertion mutants to wild-type behavior after 80 h (>3 days) of incubation (25).

Similarly, a long-chain FACS knockout mutant, KO15, of \emph{P. putida} GPO1 was delayed in its growth when supplied with octanoate as the sole carbon source but adapted after initial lag phase (15 h) to achieve growth rates and final cell densities similar to those of the parental strain (31). This suggests that other enzymes can replace the activity of the interrupted gene in these organisms.

When \emph{CA-3}\(\Delta fadD\) was supplied with short- and medium-chain phenylalkanoic and alkanoic acids with carbon chain lengths from \(C_7\) to \(C_{10}\), the growth yield of the deleted mutant was either unaffected or moderately affected (Tables 5 and 6; Fig. 5). Thus, in \emph{P. putida} CA-3 FadD is not essential but does contribute to the metabolism of medium-chain-length aromatic (\(C_{10}\)Ph and \(C_{12}\)Ph) and aliphatic (\(C_6\) to \(C_8\)) substrates (Tables 5 and 6; Fig. 5). This differs from observations by Olivera et al. and Garcia et al., who observed a complete lack of growth of mutants disrupted in a FACS supplied with phenylalkanoic acids (\(C_{10}\)Ph and \(C_{12}\)Ph) and alkanoic acids (\(C_6\) to \(C_{10}\)) (6, 25).

This again demonstrates the long-chain nature of FadD from \emph{P. putida} CA-3 in comparison to the FadD from \emph{P. putida} U. Additional genetic analysis by Olivera et al. located a second acetyl-CoA synthetase gene, \(fadD2\), upstream from \(fadD1\). Disruption of the \(fadD2\) gene did not have any effect on the catabolism of acetic, butyric, and longer fatty acids (aliphatic or aromatic) in \emph{P. putida} U. Olivera et al. suggested that \(fadD2\) was a cryptic gene, encoding a protein with a function similar to that of the \(fadD1\) product, which could be expressed only when \(fadD1\) was disrupted (25). The \(fadD\) deletion mutant in \emph{P. putida} CA-3 would appear to either not have or be incapable of inducing a second \(fadD\) to replace the activity under the conditions tested.

(ii) PHA accumulation. The PHA-accumulating ability of \emph{CA-3}\(\Delta fadD\) mimicked that of the growth pattern, with no PHA accumulation from long-chain substrates (\(C_{12}\)Ph and \(C_{14}\)) (growth on glucose), lower PHA levels than those for the wild-type strain for medium-chain substrates, and levels similar to those of the wild type for short-chain substrates. There was no adaptation of the mutant to accumulate higher levels of PHA upon extended incubation. In contrast, the \(fadD1\) mutant of \emph{P. putida} U was incapable of PHA accumulation from short-, medium-, and long-chain phenylalkanoic and alkanoic acids. However, the adapted mutant could accumulate PHA to wild-type levels (25). \emph{P. putida} GPO1 mutant KO15 accumulated twofold-lower levels of PHA with the medium-chain-length...
carbon source \((C_8)\) than did the wild-type \(P. putida\) GPO1 (31). However, long-chain substrates were not tested. \(CA-3fadD\) supplied with \(C_8\) as a substrate accumulated 3.6-fold-lower levels of PHA than did the wild-type strain (Fig. 5H). The \(CA-3fadD\) deletion mutant when complemented with a plasmid carrying a copy of \(fadD\) (CA-3\(fadD+fadD\)) exhibited an increase in the percentage of PHA accumulated over that for CA-3\(fadD\). The complemented strain regained its ability to grow on longer-chain phenylalkanoic and alkanoic acids, confirming that observed physiological changes in the mutant were due to the specific deletion of the \(fadD\) gene.

**Monomer distribution of PHA.** An increase in the percentage of short-chain monomer units incorporated into the PHA polymer was observed for the deletion mutant CA-3\(fadD\). Olivera et al. and Ren et al. reported no alternation in the monomer composition profile in polymers produced by the \(fadD1\) and KO15 adapted mutants (25, 31). The complemented strain accumulated PHA that was more similar to the wild-type PHA, but it still contained some short-chain monomers, indicating that the expression of \(fadD\) on a plasmid was not sufficient to fully restore wild-type characteristics.

**The effect of expression of an additional copy of \(fadD\) on PHA accumulation and monomer composition.** Various groups have manipulated PHA biosynthetic genes or fatty acid biosynthetic genes in an attempt to alter PHA accumulation or monomer composition (6, 26, 27, 46). In this study we noted that the expression of an extra copy of the \(fadD\) gene in \(P. putida\) CA-3 increased PHA accumulation levels up to 1.3-fold. This is in keeping with other overexpression studies (32, 44). Kraak et al. found that the expression of an additional copy of PHA polymerase \(C1\) resulted in a 1.1- and 1.9-fold increase in PHA accumulation under nitrogen-limiting and non-nitrogen-limiting conditions, respectively, in \(Pseudomonas oleovorans\) GPO1 (18).

PHA accumulated by the recombinant strain of \(P. putida\) CA-3 (CA-3+\(fadD\)) contained monomers two carbons longer than the predominant monomer, which were not present in the wild-type strain when grown on phenylalkanoic acids. Several papers report an alteration in PHA monomer composition due to the expression of an extra copy of genes such as those for PHA polymerase (\(phac\)), acetoacetyl-CoA reductase (\(phaB\)), and \(3\)-ketoacyl-ACP reductase (\(fabG\)) (27, 33). While Park et al. demonstrated that the overexpression of \(E. coli\) \(fadD\), \(fadE\), and/or \(fadL\) genes along with the PHA synthase gene from \(Pseudomonas\) sp. strain 61-3 resulted in a 1.5-fold enrichment of 3-hydroxydecanoate when cells were grown on sodium decanoate, the authors did not observe an increase in 3-hydroxydecanoic acid monomers (two carbons longer) (26). Ren et al. observed that the \(E. coli\) \(fadR\) \(fadA\) mutant (JM194) equipped with the PHA polymerase 2 from \(P. oleovorans\) GPO1 incorporated twofold-more \((R)-3\)-hydroxyhexanoic acid monomer than did the wild-type strain (32). \(E. coli\) recombinants expressing PhaC1 with either PhaJ1 or PhaJ2 accumulated larger amounts of \((R)-3\)-hydroxyhexanoic acid and \((R)-3\)-hydroxyoctanoic acid monomers (43). However, none of the studies reported PHA containing monomer units longer than that found in the PHA produced by the wild type. To the best of our knowledge, CA-3+\(fadD\) is the only recombinant strain accumulating PHA containing longer-chain monomer units than those found in the wild-type polymer when phenyl-alkanoic acids are used as a carbon source. In addition, this strain accumulates PHA with an increased proportion of longer monomer units incorporated into the polymer when alkanoic acids are used as a carbon source. Since polymer properties are determined by polymer composition, the recombinant strains (CA-3+/\(fadD\) and CA-3\(fadD+fadD\)) may offer opportunities for the generation of PHA with novel properties.

**Conclusion.** In conclusion, the long-chain FACS encoded by a \(fadD\) gene from \(P. putida\) CA-3 exhibits the highest catalytic activity and efficiency with long-chain substrates. It is solely responsible for the activation of long-chain aromatic and aliphatic substrates in vivo but also affects medium-chain-length substrate metabolism and conversion to PHA.

**ACKNOWLEDGMENTS**

We greatly appreciate the gift of pJB expression vectors from Svein Valla (Norwegian University of Science and Technology). Aisling Hume is a recipient of a University College Dublin post-graduate scholarship. Jasmina Nikodinovic-Runic is funded by the Environmental Protection Agency Ireland (ERTDI 2005-ET-LS-9-M3).

**REFERENCES**


